

For Immediate Release

For More Information:

Front Line Strategic Consulting, Inc.

650-525-1500

Stan Shelsta (x145)

Al Manzano (x135)

stan@frontlinesmc.com

al@frontlinesmc.com

NANOBIOTECHNOLOGY: OPPORTUNITIES AND TECHNICAL ANALYSIS

Increasing interest in nanobiotechnology is reflected by investment dollars, but some areas are getting more attention than others.

April 30, 2003, San Mateo, Calif. — Front Line Strategic Consulting, Inc., a leader in strategic consulting and market analysis for the Life Sciences industries, today announced the completion of its new Strategic Market Report, ***Nanobiotechnology: Opportunities and Technical Analysis***. Front Line's report includes an in-depth analysis of current and emerging technologies and nanomaterials, and their applications as drug delivery systems, imaging agents, and biosensors.

Nanoparticles of calcium phosphate constitute BioSante's CAP drug delivery system, which the company is investigating for insulin delivery. The *in vivo* distribution of imaging agents, especially for MRI, has been improved using carbon nanospheres, or Buckyballs, by Luna Innovations, and with dendrimers by Schering. Biosensor applications, including diagnostics for use *in vitro* or *ex vivo*, have been enhanced by nanomaterials such as Genicon's metal RLS particles, or superceded as with the nanoarrays produced by Bioforce Nanosciences. Industry adoption of nanobiotechnology in these applications has been rapid, and can be expected to increase in the near future.

Nanobiotechnology is a relatively young field, and academic projects far outnumber marketed products. The estimated market for nanotechnology-based life sciences products in 2003 is \$930M, and is expected to reach over \$3B in 2008. New

products coming out of development will continue to drive growth through the next five years.

“Nanotechnology is a marketing buzzword that has transitioned from electronics to biotech. Regardless of the hype, the fact is that when these tremendous engineering refinements have been incorporated into the life sciences, the benefits are undeniable,” says Eric Manning, Ph.D., analyst, strategic market reports for Front Line.

About Front Line

Headquartered in San Mateo, Calif., Front Line is a leader in strategic consulting and market analysis for the Life Sciences industries, offering strategic business intelligence through exclusive consulting engagements and comprehensive strategic market reports of key therapeutic and technology areas. Front Line was founded in 1992 and specializes in combining diligent research methodology with intelligent strategic planning for their pharmaceutical and biotechnology customers. www.frontlinesmc.com

###